Results 101 to 110 of about 9,316,170 (262)

The hidden scale: the true contribution of primary progressive multiple sclerosis to overall disability statistics

Неврология, нейропсихиатрия, психосоматика
Primary progressive multiple sclerosis (PPMS) is the most severe phenotype of the disease, characterised by a steady progression of neurological deficit from the time of onset.
A. N. Boyko, A. D. Kukushkina
doaj   +1 more source

White Matter and Perivascular Imaging Changes in Alzheimer's Disease and Cerebral Amyloid Angiopathy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Peak‐width of skeletonized mean diffusivity (PSMD) and diffusion tensor imaging–analysis along the perivascular space (DTI‐ALPS), reflecting white matter integrity and glymphatic function, are altered in Alzheimer's disease (AD).
Debina Laishram, Guangwei Du, Sangam Kanekar, Nandakumar Nagaraja   +3 more
wiley   +1 more source

Progressive Dwindling in Multiple Sclerosis: An Opportunity to Improve Care [PDF]

, 2016
Introduction In the general ageing population, 40% of deaths occur following a prolonged trajectory of “progressive dwindling,” characterised by chronic accumulation of disability and frailty, and associated with increased dependency and reduced ...
Martin, J, Joel Raffel, Raffel, JB, Nicholas, R, Jessica E Martin, Richard Nicholas   +5 more
core   +1 more source

Data‐Driven SuStaIn Model of Disability Progression in Amyotrophic Lateral Sclerosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To determine whether ordinal Subtype and Stage Inference (SuStaIn) applied to routine ALSFRS‐R item scores can identify reproducible disability progression patterns in amyotrophic lateral sclerosis (ALS) and provide clinically meaningful staging.
Giammarco Milella, Veria Vacchiano, Vittorio Velucci, Stefano Zoccolella, Rocco Liguori, Giovanni Defazio   +5 more
wiley   +1 more source

Advances in the understanding and management of multiple sclerosis phenotypes

Health Sciences Review
Multiple sclerosis is a chronic autoimmune disease of the central nervous system characterized by inflammation, demyelination, and neurodegeneration. This review synthesizes current understanding of multiple sclerosis subtypes, diagnostic criteria, and ...
Ali Msheik, Zeinab Al Mokdad, Reem Hmede, Rami Atat   +3 more
doaj   +1 more source

Mitochondrial DNA deletions and neurodegeneration in multiple sclerosis [PDF]

, 2010
Cerebral atrophy is a correlate of clinical progression in multiple sclerosis (MS). Mitochondria are now established to play a part in the pathogenesis of MS.
Turnbull, Doug M, Kim J. Krishnan, Iryna Ziabreva, Owain Howell, Graham R. Campbell, Don J. Mahad, Reynolds, Richard, Owen Howell, Mahad, Don J, Reeve, Amy K, Amy K. Reeve, Richard Reynolds, Ziabreva, Iryna, Campbell, Graham R, Lassmann, Hans, Doug M. Turnbull, Howell, Owen, Krishnan, Kim J, Hans Lassmann   +18 more
core   +1 more source

Association Between Neurofilament Light Chain and Real‐World Ambulatory Function in Progressive MS

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurofilament light chain (NfL) is a biomarker of neuroaxonal injury in multiple sclerosis (MS), yet associations with functional outcomes remain unclear. Longitudinal associations between serum NfL (sNfL) and daily step count (STEPS) from wearable devices were assessed in a large international progressive MS cohort.
Gabby B. Joseph, Megan McCune, Riley Bove, Ahmed Abdelhak, Bruce A. C. Cree, Valerie J. Block   +5 more
wiley   +1 more source

Contactin-1 and contactin-2 in cerebrospinal fluid as potential biomarkers for axonal domain dysfunction in multiple sclerosis

Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018
Background Contactin-1 and contactin-2 are important for the maintenance of axonal integrity. Objective To investigate the cerebrospinal fluid levels of contactin-1 and contactin-2 in multiple sclerosis patients and controls, and their potential use as ...
Madhurima Chatterjee, Marleen JA Koel-Simmelink, Inge MW Verberk, Joep Killestein, Hugo Vrenken, Christian Enzinger, Stefan Ropele, Franz Fazekas, Michael Khalil, Charlotte E Teunissen   +9 more
doaj   +1 more source

Functional clinical outcomes in multiple sclerosis: Current status and future prospects [PDF]

, 2015
For decades, the Expanded Disability Status Scale (EDSS) has been the principal measure of disability in clinical trials in patients with multiple sclerosis (MS) and in clinical practice.
Deleu, Dirk T., Dahdaleh, Maurice P., Alroughani, Raed, Inshasi, Jihad Said, Yamout, Bassem I., Bohlega, Saeed A., Sahraian, Mohammed A., AlTahan, Abdulrahman M., Rieckmann, Peter, Al-Jumah, Mohammed A., Alsharoqi, Isa Ahmed, Deleu, Dirk, Aljumah, Mohammed, Daif, Abdulkader Kader M., Karabudak, Rana, Alroughani, Raed A., Sahraian, Mohammad Ali, Inshasi, Jihad S., Dahdaleh, Maurice, Alsharoqi, I. Ahmed, Amous, Amer, Daif, Abdulkader   +21 more
core   +1 more source

Autoimmune Comorbidities as Modifiers of Phenotypic Heterogeneity in Facioscapulohumeral Dystrophy

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Facioscapulohumeral dystrophy type 1 (FSHD1) shows clinical heterogeneity that is only partly explained by D4Z4 repeat unit (RU) size. Although immune and inflammatory mechanisms may contribute to disease variability, the prevalence and clinical impact of autoimmune diseases in FSHD remain unclear.
Jonathan Pini, Giulia Tammam, Andra Ezaru, Manuela Gambella, Benoît Sanson, Luisa Villa, Michele Cavalli, Mihai‐Bogdan Ioncea, Angela Puma, Sabrina Sacconi   +9 more
wiley   +1 more source